ArticleThe Journal of allergy and clinical immunology2025

High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo.

Daniel Brigger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.